Nanotechnology methods for neurological diseases and brain tumors : drug delivery across the blood--brain barrier /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores principales: �Ozdemir, Yasemin G�ursoy (Autor), Pehlivan, Sibel Bozdag (Autor), Sekerdag, Emine (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London : Academic Press, [2017]
Temas:
Blood-brain barrier > Effect of drugs on.
Blood-brain barrier > Metabolism.
Drug development.
Nanotechnology.
Blood-Brain Barrier > metabolism
Central Nervous System Agents > pharmacokinetics
Central Nervous System Diseases > drug therapy
Blood-Brain Barrier > drug effects
Drug Delivery Systems
Nanomedicine > methods
Nanotechnology
Barri�ere h�emato-enc�ephalique > Effets des m�edicaments sur.
Barri�ere h�emato-enc�ephalique > M�etabolisme.
M�edicaments > D�eveloppement.
Nanotechnologie.
MEDICAL > Pharmacology.
Drug development
Electronic books.
Internet Resources.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover
  • Title Page
  • Copyright Page
  • Contents
  • List of Contributors
  • About the Editors
  • Preface
  • References
  • Part 1
  • The Rationale to Reach the Brain
  • Chapter 1
  • Anatomy and Physiology of the Blood-Brain Barrier
  • 1
  • Introduction
  • 2
  • Structure of the BBB
  • 3
  • BBB Developmental Steps
  • 4
  • Transport Across the BBB
  • 4.1
  • Passive Transfer or Diffusion
  • 4.2
  • Solute Carrier System
  • 4.3
  • ATP-Binding Transporters of Efflux Transporters
  • 4.4
  • Transport of Macromolecules
  • 5
  • Conclusions
  • Abbreviations
  • References
  • Chapter 2
  • Blood-Brain Barrier: Genomics, Proteomics, Disease Targets, and Drug Delivery
  • 1
  • Introduction
  • 2
  • Blood-Brain Barrier Genomics
  • 2.1
  • Genome Products Selectively Expressed at the BBB
  • 2.2
  • Methods Used in BBB Genomics
  • 3
  • Blood-Brain Barrier Proteomics
  • 4
  • Disease Targets
  • 5
  • Drug Delivery
  • 5.1
  • Recombinant Proteins and Monoclonal Antibodies
  • 5.2
  • Gene-Based Systems
  • 6
  • Conclusions
  • Abbreviations
  • References
  • Chapter 3
  • Brain and the Drug Transporters
  • 1
  • Introduction
  • 2
  • Brain Transporters
  • 2.1
  • ABC Drug Transporters
  • 2.1.1
  • ABCB1: P-Glycoprotein
  • 2.1.2
  • ABCC: Multidrug Resistance-Associated Protein
  • 2.1.3
  • ABCG2: Breast Cancer Resistance Protein
  • 2.2
  • SLC Transporters
  • 2.2.1
  • SLCO1: Organic Anion Transporting Polypeptides
  • 2.2.2
  • SLC22A6-8: Organic Anion Transporters
  • 2.2.3
  • SLC22A: Organic Cation Transporters
  • 2.2.4
  • SLC16A: Monocarboxylate Transporters
  • 2.2.5
  • SLC15A: Oligopeptide Transporters
  • 2.2.6
  • Nucleoside Transporters
  • 3
  • Conclusions
  • Abbreviations
  • References
  • Chapter 4
  • Drug Delivery to the Brain: Pharmacokinetic Concepts
  • 1
  • Introduction
  • 2
  • CNS Drug Delivery
  • 2.1
  • Barriers to CNS Drug Delivery
  • 2.2
  • BBB Transport Mechanism
  • 2.2.1
  • Passive Diffusion
  • 2.2.2
  • Endocytosis.
  • 2.2.3
  • Active Transport
  • 2.3
  • Rate of Drug Delivery to the Brain
  • 2.4
  • Extent of Drug Delivery to the Brain
  • 3
  • Intrabrain Distribution
  • 4
  • Conclusions
  • Abbreviations
  • References
  • Part 2
  • Nose-to-Brain Drug Delivery
  • Chapter 5
  • Nasal Physiology and Drug Transport
  • 1
  • Introduction
  • 2
  • Anatomy of the Nose
  • 3
  • Nasal Transport Mechanisms
  • 3.1
  • Mucus Layer
  • 3.2
  • Olfactory Pathway
  • 3.3
  • Trigeminal Pathway
  • 4
  • Factors Affecting Nose-to-Brain Transport
  • 5
  • Principles of Drug Administration
  • 6
  • Conclusions
  • Abbreviations
  • References
  • Chapter 6
  • Challenges of the Nose-to-Brain Route
  • 1
  • Introduction
  • 2
  • Nose-to-Brain Research
  • 3
  • Overcoming Barriers in Nasal Drug Delivery
  • 3.1
  • Physiological Possibilities
  • 3.2
  • Surface Modifications of Drugs
  • 3.3
  • Nanoparticle Formulations
  • 4
  • In Vitro and In Vivo Models for Nasal Drug Delivery
  • 5
  • Conclusions
  • Abbreviations
  • References
  • Part 3
  • Nanoscience in Targeted Brain Drug Delivery
  • Chapter 7
  • Nanoscience in Targeted Brain Drug Delivery
  • 1
  • Importance and Application of Nanotechnology-Based Brain Drug Delivery Systems
  • 1.1
  • Nanoparticles
  • 1.1.1
  • Metallic Nanoparticles
  • 1.1.2
  • Silica Nanoparticles
  • 1.1.3
  • Polymeric Nanoparticles
  • 1.1.4
  • Lipid Nanoparticles
  • 1.2
  • Liposomes
  • 1.3
  • Dendrimers
  • 1.4
  • Polymeric Micelles
  • 1.5
  • Carbon Nanotubes
  • 2
  • Neurotoxicity
  • 3
  • Clinical Considerations
  • 4
  • Ethical and Regulatory Issues
  • 5
  • Conclusions
  • Abbreviations
  • References
  • Part 4
  • Brain-Targeted Experimental Models
  • Chapter 8
  • In Vitro CNS Models
  • 1
  • Introduction
  • 1.1
  • Development of In Vitro Cell Culture Models
  • 2
  • Cellular Structure of the BBB
  • 3
  • Tight Junctions and In Vitro Paracellular Barrier Characterization
  • 4
  • Cell Culture Models.
  • 4.1
  • 2D In Vitro BBB Models: Monoculture and Coculture
  • 4.1.1
  • Noncerebral-Based In Vitro Cell Culture Models
  • 4.1.2
  • Cerebral-Based In Vitro Cell Culture Models
  • 4.1.2.1
  • Primary Brain Endothelial Cell Culture
  • 4.1.2.2
  • Immortalized Cell Lines
  • 4.1.3
  • BBB Models of Cocultures
  • 4.1.3.1
  • Coculture of Endothelial Cells With Astrocytes
  • 4.1.3.2
  • Coculture of Endothelial Cells With Pericytes
  • 4.1.3.3
  • Coculture of Endothelial Cells With Neurons and Microglia
  • 4.1.3.4
  • Coculture of Stem Cells/Stem Cell-Derived Cells
  • 4.2
  • 3D In Vitro BBB Models
  • 4.3
  • Dynamic Models of the BBB
  • 4.4
  • Microfluidic BBB Models
  • 4.5
  • Disease Models
  • 5
  • Comparison of In Vitro Cell Culture Models
  • 6
  • Conclusions and Future Outlook
  • Abbreviations
  • References
  • Chapter 9
  • In Vivo/In Situ Animal Models
  • 1
  • Introduction
  • 2
  • Animal Models of Alzheimer's Disease
  • 3
  • Animal Models of Parkinson's Disease
  • 4
  • Animal Models of Huntington's Disease
  • 5
  • Animal Models of Depression
  • 6
  • Animal Models of Anxiety
  • 7
  • Animal Models of Schizophrenia
  • 8
  • Animal Models of Pain
  • 9
  • Animal Models of Stroke
  • 10
  • Animal Models of Brain Tumor
  • 11
  • Conclusions
  • Abbreviations
  • References
  • Chapter 10
  • Microdialysis and Brain Perfusion
  • 1
  • Introduction
  • 2
  • Techniques in Relation to Measured Entities
  • 3
  • Microdialysis
  • 3.1
  • Aspects of Microdialysis in Relation to NC Studies
  • 3.2
  • Methodological Aspects
  • 3.2.1
  • In Vitro Preparations
  • 3.2.2
  • In Vivo Preparations
  • 3.3
  • Microdialysis Study Design of Nanodelivery to the Brain
  • 4
  • Open Flow Microperfusion
  • 5
  • In Situ Brain Perfusion
  • 6
  • Discussion
  • Abbreviations
  • References
  • Chapter 11
  • Neuroimaging: Techniques and General Applications
  • 1
  • Introduction
  • 2
  • Ultrasonography
  • 3
  • Computed Tomography.
  • 6
  • Tolerance Induction
  • 7
  • Neuroprotection
  • 8
  • Nanotechnology in Nonautoimmune Neuroinflammation
  • 9
  • Neuroinflammatory Adverse Effects of Nanoparticles
  • 10
  • Concluding Remarks
  • Abbreviations
  • References
  • Chapter 16
  • Infectious Diseases of the Brain
  • 1
  • Introduction
  • 2
  • Brain Infections
  • 2.1
  • Meningitis
  • 2.1.1
  • Bacterial Meningitis
  • 2.1.1.1
  • Etiology of Bacterial Meningitis
  • 2.1.1.2
  • Treatment
  • 2.1.1.3
  • Novel Antibiotics
  • 2.1.1.3.1
  • Cefepime
  • 2.1.1.3.2
  • Meropenem
  • 2.1.1.3.3
  • Daptomycin
  • 2.1.1.3.4
  • Televancin
  • 2.1.1.4
  • New Treatment Options
  • 2.1.1.4.1
  • Adjunctive Treatment With Corticosteroid
  • 2.1.1.4.2
  • Nonbacteriolytic Antibiotics
  • 2.1.1.4.3
  • Vaccines
  • 2.1.2
  • Viral Meningitis
  • 2.1.2.1
  • Treatment
  • 2.2
  • Encephalitis
  • 2.2.1
  • Etiology of Encephalitis
  • 2.3
  • Brain Abscesses
  • 2.3.1
  • Etiology of Brain Abscess
  • 2.3.2
  • Treatment
  • 3
  • Consideration of the Treatment of Brain Infections
  • 3.1
  • Lack of Information on Microbial Translocation into the CNS
  • 3.2
  • BBB and BCSFB
  • 3.3
  • Antibiotic Resistance
  • 4
  • Nanotechnological Approach and Recent Trends in Brain Infection Treatments
  • 4.1
  • Polymeric Nanoparticles
  • 4.2
  • Polymeric Micelles
  • 4.3
  • Solid Lipid Nanoparticles
  • 4.4
  • Cationic Antimicrobial Peptides
  • 4.5
  • Liposomes
  • 4.6
  • Cell-Mediated Drug Delivery
  • 5
  • Conclusions
  • Abbreviations
  • References
  • Part 6
  • Brain Tumors
  • Chapter 17
  • Brain Tumors
  • 1
  • Introduction
  • 2
  • Types of Brain Tumors
  • 2.1
  • Tumor Cell Kinetics
  • 3
  • Conventional Treatment Approaches
  • 3.1
  • Surgery
  • 3.2
  • Radiation Therapy
  • 3.3
  • Chemotherapy
  • 4
  • Blood-Brain Tumor Barrier
  • 5
  • Overcoming the BBB
  • 5.1
  • Drug Modification
  • 5.2
  • Reversible Opening of the BBB
  • 5.3
  • Implantation of Drug Delivery Systems.
  • 6
  • Nanotechnology-Based Drug Delivery Systems.

Ejemplares similares